The bill amends the "Right to Try Act" to enhance access to experimental treatments for patients with advanced, life-threatening, or severely debilitating illnesses. It introduces new definitions and clarifications regarding eligible patients and facilities, as well as the conditions under which investigational drugs, biological products, or devices can be provided. Notably, the bill specifies that health care providers cannot face sanctions for recommending or providing these treatments, and it outlines the responsibilities of health insurers concerning coverage for such treatments. Additionally, it establishes that patients must provide written, informed consent before receiving these investigational treatments.

Furthermore, the bill includes provisions that protect patients' heirs from liability for debts related to treatments if the patient dies while undergoing such treatments. It also prohibits state officials from obstructing access to investigational treatments and ensures that manufacturers are not liable for harm caused to patients if they comply with the act's terms. The amendments aim to create a more supportive framework for patients seeking experimental therapies while safeguarding the rights of healthcare providers and manufacturers involved in the process.

Statutes affected:
House Introduced Bill: 333.26451